13F Holdings
中文EN

PMN ProMIS Neurosciences Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1374339 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY62.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-152.3%
ROA-113.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.4%
Debt / equity0.00x
Current ratio8.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio7.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$33.38M$10.64M$7.88M$16.09M$4.63M
SG&A expense$6.79M$6.19M$6.38M$7.29M$3.66M
Operating income-$40.17M-$16.83M-$14.26M-$23.38M-$8.29M
Interest expense———$282,064$416,286
Income tax—$0$0$0—
Net income-$39.72M$2.78M-$13.21M-$18.06M-$9.79M
EBITDA——-$14.26M-$23.37M-$8.25M
EPS (basic)-22.612.68-1.07-2.41-1.69
EPS (diluted)-22.612.63-1.07-2.41-1.69
Weighted avg. shares (diluted)1.76M1.06M12.29M7.50M5.79M
Balance sheet
Cash & equivalents$6.12M$13.29M$12.60M$5.88M$16.94M
Short-term investments$33,753$33,051$32,358$31,009$33,248
Current assets$9.18M$18.91M$13.62M$6.90M$17.71M
PP&E, net———$321$4,671
Intangibles———$20,838$27,614
Total assets$9.18M$18.91M$13.62M$6.92M$17.75M
Current liabilities$10.41M$2.22M$9.35M$6.41M$929,074
Long-term debt——$0—$3.91M
Total debt——$0—$3.91M
Total liabilities$10.44M$2.42M$9.87M$8.27M$12.09M
Shareholders' equity-$1.26M$16.49M$3.75M-$1.35M$5.66M
Net debt——-$12.60M—-$13.04M
Shares outstanding2.15M1.31M18.89M8.58M7.20M
Cash flow statement
Operating cash flow-$28.12M-$27.18M-$10.84M-$17.03M-$9.31M
Capital expenditure———$1,981$6,044
Free cash flow———-$17.04M-$9.31M
Investing cash flow-$702-$693-$1,349-$1,981$94,618
Financing cash flow$20.94M$27.88M$17.75M$6.49M$25.52M
Depreciation & amortization——$321$6,144$40,576
Stock-based compensation$857,628$825,808$271,542$487,630$515,629

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.